Location · El Paso, TX
Clinical trials in El Paso, TX
78 recruiting studies have a site in El Paso, and 9 of them accept healthy volunteers.
78 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- El Paso, TX + 35 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
AstraZeneca
- Location
- El Paso, TX + 70 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- El Paso, TX + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- El Paso, TX + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
Trevi Therapeutics
- Location
- El Paso, TX + 21 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 1/Phase 2
Phase 1b/2 Study of IV Sarilumab in Adult With RA
Sanofi
- Location
- El Paso, TX + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
Novartis Pharmaceuticals
- Location
- El Paso, TX + 17 other US sites
- Eligibility basics
- Ages 12–65
- RecruitingPhase 3
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
AbbVie
- Location
- El Paso, TX + 24 other US sites
- Eligibility basics
- Ages 45+
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
AstraZeneca
- Location
- El Paso, TX + 53 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- El Paso, TX + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- El Paso, TX + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Regeneron Pharmaceuticals
- Location
- El Paso, TX + 55 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- El Paso, TX + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk A/S
- Location
- El Paso, TX + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- El Paso, TX + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
GlaxoSmithKline
- Location
- El Paso, TX + 50 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
Yarrow Bioscience, Inc.
- Location
- El Paso, TX + 21 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- El Paso, TX + 69 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
AstraZeneca
- Location
- El Paso, TX + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Avalyn Pharma Inc.
- Location
- El Paso, TX + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Jazz Pharmaceuticals
- Location
- El Paso, TX + 20 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 2
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Supernus Pharmaceuticals, Inc.
- Location
- El Paso, TX + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
AstraZeneca
- Location
- El Paso, TX + 18 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
ViiV Healthcare
- Location
- El Paso, TX + 36 other US sites
- Eligibility basics
- Ages 12+